Neonatal drug withdrawal

Mark L. Hudak, Rosemarie C. Tan, Daniel A.C. Frattarelli, Jeffrey L. Galinkin, Thomas P. Green, Kathleen A. Neville, Ian M. Paul, John N. Van Den Anker, Mary Hegenbarth, Matthew Knight, Robert E. Shaddy, Wayne R. Snodgrass, John J. Alexander, Nancy C. Chescheir, Janet D. Cragan, Michael J. Rieder, Adelaide Robb, Hari C. Sachs, Anne Zajicek, George P. GiacoiaMark Del Monte, Raymond J. Koteras, Lu Ann Papile, Jill E. Baley, Vinod K. Bhutani, Waldemar A. Carlo, James J. Cummings, Praveen Kumar, Richard A. Polin, Kasper S. Wang, Kristi L. Watterberg, David H. Adamkin, Wanda D. Barfield, George Macones, Ann L. Jefferies, Rosalie O. Mainous, Tonse N.K. Raju, William H. Barth, Jim Couto

Research output: Contribution to journalArticlepeer-review

703 Scopus citations


Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.

Original languageEnglish
Pages (from-to)e540-e560
Issue number2
StatePublished - Feb 2012


  • Abstinence syndrome
  • Benzodiazepine
  • Cocaine
  • Drug withdrawal
  • Fentanyl
  • Heroin
  • Methadone
  • Methamphetamine
  • Neonate
  • Opioid
  • SSRI

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Neonatal drug withdrawal'. Together they form a unique fingerprint.

Cite this